BioSpace News Archive

Endogenex, Inc., a clinical stage medical device company, is proud to announce the addition of Stacey Pugh as Chief Executive Officer (CEO).

High scores across the board put company in the top 5% of glass/glass product manufacturers

mbiomics GmbH, a pioneering microbiome biotech company developing the first generation of effective microbiome-based therapeutics announced today the first closing of EUR 13 million (US$ 15 million) of a series A financing round led by MIG Capital. High-Tech Gründerfonds and Bayern Kapital joined the funding round together with a pool of private seed investors.

Cala, the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced meeting the primary endpoint on an interim analysis of a prospective, randomized, controlled study.

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the European Medicines Agency (EMA) has validated the application for its self-developed anti-PD-1 monoclonal antibody (mAb) HANSIZHUANG (serplulimab), in combination with chemotherapy (carboplatin and etoposide), for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

Journey Biosciences announced that it has become the first company to receive a T1D Moonshot Fellowship in StartUp Health’s T1D Moonshot, a bold new initiative to inspire, educate and empower founders and funders to ensure “that everyone with Type 1 diabetes has the tools and resources necessary to thrive.”

BioGX announced accelerated adoption of their high performance Sample-Ready™ PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full-year ended December 31, 2022.

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent operational highlights.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Herbert Harris, M.D., Ph.D., Executive Vice President, Translational Medicine of Tonix Pharmaceuticals, delivered an oral presentation on March 23, 2023, at the Rare Disease Innovation and Partnership Summit being held as a hybrid event in Philadelphia, Pa.